AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39288507 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary geriatric follow-up
Number of subjects: 363
Study 39288507 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 363
Study 39288528 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC-OX (90 mg/m2) combined with systemic nivolumab
Number of subjects: 18
Study 39288528 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC-OX and nivolumab
Number of subjects: 18
Study 39288676 — intervention group
Group type: EXPERIMENTAL
Intervention: High nutritional status trajectory
Number of subjects: 112
Study 39288676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nutritional status trajectory
Number of subjects: 112
Study 39288676 — intervention group
Group type: COMPARATOR
Intervention: Symptom severity
Number of subjects: 112
Study 39288676 — intervention group
Group type: COMPARATOR
Intervention: Older age and surgical complications
Number of subjects: 112
Study 39288779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemoradiotherapy
Number of subjects: 1060
Study 39288779 — intervention group
Group type: COMPARATOR
Intervention: Placebo-chemoradiotherapy
Number of subjects: 1060
Study 39288781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant pembrolizumab (200 mg IV every 3 weeks)
Number of subjects: 797
Study 39288781 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant placebo (IV every 3 weeks) plus cisplatin-based chemotherapy followed by 13 cycles of adjuvant placebo (IV every 3 weeks)
Number of subjects: 797
Study 39288781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab plus chemotherapy
Number of subjects: 797
Study 39288781 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant placebo plus chemotherapy
Number of subjects: 797
Study 39288844 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous nivolumab (1200 mg every 4 weeks)
Number of subjects: 495
Study 39288844 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 495
Study 39288943 — intervention group
Group type: EXPERIMENTAL
Intervention: MESA intervention (2-session online intervention with ART information and personalized feedback + ART standard of care)
Number of subjects: 152
Study 39288943 — intervention group
Group type: EXPERIMENTAL
Intervention: MESA intervention
Number of subjects: 152
Study 39288943 — intervention group
Group type: COMPARATOR
Intervention: SH control (information on healthy eating and physical activity + ART standard of care)
Number of subjects: 152
Study 39289010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 18
Study 39289023 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence module with wound monitoring platform plus standard postoperative wound care
Number of subjects: 120
Study 39289023 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative wound care only
Number of subjects: 120
Study 39289024 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking (EAW) alone
Number of subjects: 16
Study 39289024 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeletal-assisted walking plus transcutaneous spinal cord stimulation (EAW+tSCS)
Number of subjects: 16
Study 39289029 — intervention group
Group type: EXPERIMENTAL
Intervention: E6742 100 mg
Number of subjects: 17
Study 39289029 — intervention group
Group type: EXPERIMENTAL
Intervention: E6742 200 mg
Number of subjects: 17
Study 39289029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 39289057 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole/magnesium hydroxide 40/350 mg
Number of subjects: 49
Study 39289057 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated esomeprazole 40 mg
Number of subjects: 49
Study 39289059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0
Study 39289059 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine-rituximab (R-bendamustine)
Number of subjects: 0
Study 39289093 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing arm (n=34)
Number of subjects: 102
Study 39289093 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care arm (n=34)
Number of subjects: 102
Study 39289093 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=34)
Number of subjects: 102
Study 39289145 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg daily)
Number of subjects: 216
Study 39289145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 39289218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hugo™ RAS system
Number of subjects: 40
Study 39289373 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive deep brain stimulation (aDBS)
Number of subjects: 68
Study 39289377 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mcg single dose of H10ssF vaccine
Number of subjects: 25
Study 39289377 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mcg two doses of H10ssF vaccine
Number of subjects: 25
Study 39289471 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise focusing on quadriceps muscles for 3 months
Number of subjects: 7
Study 39289473 — intervention group
Group type: EXPERIMENTAL
Intervention: Postocclusive reactive hyperemia (PORH)
Number of subjects: 64
Study 39289473 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 64
Study 39289473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 64
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in survivors (30 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in survivors (180 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients aged < 65 years (30 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR) in patients aged < 65 years (180 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC AUC for NLR in patients aged < 65 years (30 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC AUC for NLR in patients aged < 65 years (180 days)
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression for NLR
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression for age
Number of subjects: 851
Study 39289610 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis for 180 days mortality
Number of subjects: 851
Study 39289646 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting intervention arm
Number of subjects: 640
Study 39289646 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control arm
Number of subjects: 640
Study 39289685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral synbiotics
Number of subjects: 0
Study 39289685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39289739 — intervention group
Group type: EXPERIMENTAL
Intervention: fSCIG 10%
Number of subjects: 42
Study 39289750 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive decision support tool (DST)
Number of subjects: 132
Study 39289760 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pneumatic tourniquet application
Number of subjects: 34
Study 39289760 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet application
Number of subjects: 34
Study 39289825 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (TU)
Number of subjects: 148
Study 39289825 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (Training)
Number of subjects: 148
Study 39289825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of testosterone therapy (TU) and progressive resistance training (Combo)
Number of subjects: 148
Study 39289825 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Controls)
Number of subjects: 148
Study 39290050 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote electrical neuromodulation (REN)
Number of subjects: 22
Study 39290050 — intervention group
Group type: COMPARATOR
Intervention: Intravenous interventions (typical care)
Number of subjects: 22
Study 39290050 — intervention group
Group type: EXPERIMENTAL
Intervention: REN
Number of subjects: 22
Study 39290050 — intervention group
Group type: COMPARATOR
Intervention: Typical care (intravenous metoclopramide and ketorolac)
Number of subjects: 22
Study 39290059 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongest Families Smart Website (SFSW)
Number of subjects: 464
Study 39290059 — intervention group
Group type: COMPARATOR
Intervention: Education Control (EC)
Number of subjects: 464
Study 39290122 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow derived mesenchymal stromal cells (BM-MSCs) transplantation after lunate core decompression
Number of subjects: 3
Study 39290129 — intervention group
Group type: EXPERIMENTAL
Intervention: Agent PCB
Number of subjects: 262
Study 39290129 — intervention group
Group type: COMPARATOR
Intervention: SeQuent Please PCB
Number of subjects: 262
Study 39290519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for smoking cessation, n = 30, implemented in group-based sessions over an eight-week period
Number of subjects: 60
Study 39290519 — intervention group
Group type: COMPARATOR
Intervention: Control Group, n = 30, including a brief psychoeducation advice about smoking cessation
Number of subjects: 60
Study 39290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 50 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96
Study 39290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 100 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96
Study 39290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 0 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96
Study 39290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy) 150 mg/kg with TBI 2 Gy, ATG and fludarabine
Number of subjects: 96
Study 39290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged ≥50 years
Number of subjects: 96
Study 39290680 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with the MitraClip device plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 39290680 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study 39290817 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean transvalvular pressure gradient to effective orifice area ratio (MG/EOA)
Number of subjects: 188
Study 39290817 — intervention group
Group type: EXPERIMENTAL
Intervention: MG/EOA ratio
Number of subjects: 188
Study 39290861 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 7752
Study 39290861 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 7752
Study 39290981 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3326595 400 mg once daily
Number of subjects: 30
Study 39290981 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3326595 300 mg once daily
Number of subjects: 30
Study 39290981 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3326595
Number of subjects: 30
Study 39291052 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic drugs (alprazolam, bromazepam, lorazepam, meprobamate, midazolam, oxazepam)
Number of subjects: 8
Study 39291052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 8
Study 39291052 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 8
Study 39291052 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 8
Study 39291052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 8
Study 39291193 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome-driven approach utilizing renal biopsies from AL amyloidosis participants
Number of subjects: 0
Study 39291193 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scarring injury and amyloid score (AS) assigned to each biopsy
Number of subjects: 0
Study 39291193 — intervention group
Group type: COMPARATOR
Intervention: Expression data compared to healthy living donors and focal segmental glomerulosclerosis (FSGS) profiles
Number of subjects: 0
Study 39291206 — intervention group
Group type: EXPERIMENTAL
Intervention: Felzartamab
Number of subjects: 31
Study 39291212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 60
Study 39291212 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 60
Study 39291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided modular online intervention (8 modules, ~20 min each)
Number of subjects: 1811
Study 39291249 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1811
Study 39291249 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided modular online intervention
Number of subjects: 1811
Study 39291303 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab-assisted multi-food oral immunotherapy (mOIT)
Number of subjects: 0
Study 39291332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for Breast Cancer
Number of subjects: 0
Study 39291332 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39291473 — intervention group
Group type: EXPERIMENTAL
Intervention: BE FAST
Number of subjects: 174
Study 39291473 — intervention group
Group type: COMPARATOR
Intervention: FAST
Number of subjects: 174
Study 39291483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 186
Study 39291483 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 186
Study 39291487 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week rehabilitation intervention
Number of subjects: 349
Study 39291487 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 349
Study 39291498 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (MFS-T)
Number of subjects: 70
Study 39291498 — intervention group
Group type: COMPARATOR
Intervention: Control group (MFS-C)
Number of subjects: 70
Study 39291502 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins)
Number of subjects: 89462
Study 39291502 — intervention group
Group type: COMPARATOR
Intervention: SMuRFs (standard modifiable cardiovascular risk factors)
Number of subjects: 89462
Study 39291502 — intervention group
Group type: EXPERIMENTAL
Intervention: SMuRF-less patients
Number of subjects: 89462
Study 39291635 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated aortic pulse wave velocity (aPWV)
Number of subjects: 1046
Study 39291867 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 1676
Study 39291867 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 1 (including 5 pretreatment predictors)
Number of subjects: 1676
Study 39291867 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (including 2 treatment-related predictors)
Number of subjects: 1676
Study 39291967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucagon
Number of subjects: 28
Study 39291967 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 28
Study 39292112 — intervention group
Group type: COMPARATOR
Intervention: Manual Therapy (MT)
Number of subjects: 46
Study 39292112 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-massage (ES) combined with Manual Therapy (MT)
Number of subjects: 46
Study 39292188 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool DNA-based SDC2 methylation test
Number of subjects: 1124
Study 39292351 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataXRT
Number of subjects: 43
Study 39292351 — intervention group
Group type: COMPARATOR
Intervention: Standard of care and Mepitel Film (MF)
Number of subjects: 43
Study 39292433 — intervention group
Group type: EXPERIMENTAL
Intervention: Donanemab (13 doses over 1 year)
Number of subjects: 0
Study 39292443 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast cream, 0.15%
Number of subjects: 1337
Study 39292443 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 1337
Study 39292452 — intervention group
Group type: EXPERIMENTAL
Intervention: YAWNS-1 (Sleepwell package)
Number of subjects: 565
Study 39292452 — intervention group
Group type: EXPERIMENTAL
Intervention: YAWNS-2 (updated booklets)
Number of subjects: 565
Study 39292452 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 565
Study 39292452 — intervention group
Group type: EXPERIMENTAL
Intervention: YAWNS-1
Number of subjects: 565
Study 39292459 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (via EHR alert)
Number of subjects: 6
Study 39292459 — intervention group
Group type: COMPARATOR
Intervention: Usual care (normal saline)
Number of subjects: 6
Study 39292927 — intervention group
Group type: EXPERIMENTAL
Intervention: Axatilimab 0.3 mg/kg every 2 weeks
Number of subjects: 241
Study 39292927 — intervention group
Group type: EXPERIMENTAL
Intervention: Axatilimab 1 mg/kg every 2 weeks
Number of subjects: 241
Study 39292927 — intervention group
Group type: EXPERIMENTAL
Intervention: Axatilimab 3 mg/kg every 4 weeks
Number of subjects: 241
Study 39292928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily for 24 weeks)
Number of subjects: 144
Study 39292928 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 24 weeks)
Number of subjects: 144
Study 39292975 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib
Number of subjects: 417
Study 39292975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 39292994 — intervention group
Group type: EXPERIMENTAL
Intervention: Early maturing girls
Number of subjects: 81
Study 39292994 — intervention group
Group type: COMPARATOR
Intervention: Late maturing girls
Number of subjects: 81
Study 39293025 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative immunoprecipitation mass spectrometry (QIP-MS)
Number of subjects: 0
Study 39293025 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation flow (NGF) cytometry
Number of subjects: 0
Study 39293025 — intervention group
Group type: EXPERIMENTAL
Intervention: QIP-MS
Number of subjects: 0
Study 39293025 — intervention group
Group type: COMPARATOR
Intervention: NGF and MS
Number of subjects: 0
Study 39293050 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming-based dementia educational program (90 minutes duration)
Number of subjects: 0
Study 39293082 — intervention group
Group type: EXPERIMENTAL
Intervention: UM171 during LVV transduction
Number of subjects: 0
Study 39293082 — intervention group
Group type: COMPARATOR
Intervention: Cells transduced with UM171
Number of subjects: 0
Study 39293083 — intervention group
Group type: EXPERIMENTAL
Intervention: M+R (magrolimab plus rituximab)
Number of subjects: 132
Study 39293083 — intervention group
Group type: EXPERIMENTAL
Intervention: M+R-GemOx (magrolimab plus rituximab plus gemcitabine-oxaliplatin)
Number of subjects: 132
Study 39293201 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 150
Study 39293201 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Ball
Number of subjects: 150
Study 39293201 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 39293214 — intervention group
Group type: EXPERIMENTAL
Intervention: vYF vaccine (4, 5 or 6 Log CCID)
Number of subjects: 100
Study 39293214 — intervention group
Group type: EXPERIMENTAL
Intervention: vYF vaccine
Number of subjects: 100
Study 39293214 — intervention group
Group type: COMPARATOR
Intervention: YF-VAX vaccine
Number of subjects: 100
Study 39293461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutetium-177
Number of subjects: 130
Study 39293461 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 130
Study 39293462 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label, intravenous treatment (specific treatment not mentioned)
Number of subjects: 468
Study 39293494 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step increase in temperature (34-37°C)
Number of subjects: 21
Study 39293494 — intervention group
Group type: EXPERIMENTAL
Intervention: No temperature increase (started and remained at 37°C)
Number of subjects: 21
Study 39293494 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step increase (31 to 34 to 37°C)
Number of subjects: 21
Study 39293494 — intervention group
Group type: COMPARATOR
Intervention: Overall comfort across all study arms
Number of subjects: 21
Study 39293515 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986365 (CC-94676) at doses of 400-900 mg twice daily (n = 60)
Number of subjects: 95
Study 39293515 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986365 (CC-94676)
Number of subjects: 95
Study 39293778 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (RT) plus bone-loading exercises and placebo capsules
Number of subjects: 308
Study 39293778 — intervention group
Group type: COMPARATOR
Intervention: No RT and placebo capsules
Number of subjects: 308
Study 39293786 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary magnetic resonance angiography (CMRA)
Number of subjects: 201
Study 39293786 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 201
Study 39294027 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 3840
Study 39294027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 3840